C4 Therapeutics, Inc. (CCCC) is a publicly traded Healthcare sector company. As of May 21, 2026, CCCC trades at $3.26 with a market cap of $356.03M and a P/E ratio of -2.56. CCCC moved +5.31% today. Year to date, CCCC is +61.58%; over the trailing twelve months it is +121.62%. Its 52-week range spans $1.09 to $7.14. Analyst consensus is strong buy with an average price target of $13.60. Rallies surfaces CCCC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes CCCC SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $3.26 |
| Market Cap | $356.03M |
| P/E Ratio | -2.56 |
| EPS | $-1.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.14 |
| 52-Week Low | $1.09 |
| Volume | 364 |
| Avg Volume | 0 |
| Revenue (TTM) | $35.95M |
| Net Income | $-104.99M |
| Gross Margin | 0.00% |
6 analysts cover CCCC: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.60.